Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or its methyl-d3 deuterated form

JP7644009B2Active Publication Date: 2025-03-11OGEDA SA
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021535842
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2019-12-20
Publication Date
2025-03-11
Estimated Expiration
2039-12-20

Smart Images

  • Figure 0007644009000001
    Figure 0007644009000001
  • Figure 0007644009000002
    Figure 0007644009000002
  • Figure 0007644009000003
    Figure 0007644009000003
Patent Text Reader

Abstract

The present invention relates to compound (I): [Formula 1] TIFF2022520698000050.tif3266, wherein R 1 represents methyl or methyl-d3 and thus corresponds to 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or its deuterated form, methyl-d3. These compounds are useful as key intermediates in the synthesis of pharmaceutical compounds, particularly fezolinethant and deuterated fezolinethant.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • JP1975031760A

  • Production of thiadiazoleacetic acid derivative

    JP1992077477A

  • Pharmaceutical compound

    JP1992224570A

  • Novel chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine as a selective NK-3 receptor antagonist, its pharmaceutical composition, method of use in NK-3 receptor-mediated disorders, and chiral synthesis.

    JP2014531464A